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Lung cancer:
New evidence -
new realities - 
new challenges
The past years have yielded a wealth of new data on how to improve the outcome for 
patients with lung cancer, in particular with non-small cell lung cancer. 
Past achievements were largely based on the recognition that the delivery of optimal 
therapy mandates the involvement of a dedicated multidisciplinary team. Now, the ma-
jor new advances are the suggestion that screening for patients with a high risk for lung 
cancer can be benecial, that new radiotherapy techniques allow potentially curative 
treatment in early localized disease, and that the molecular analysis of tumor tissue al-
lows to provide effective therapy beyond the standard chemotherapy to selected subsets 
of patients whose tumors harbor specic molecular features.
With new evidence gained from clinical studies, the reality of clinical practice has 
changed substantially. Patients today will ask their physicians about incidental lung-
cancer screenings. As outlined in the article by Mark and colleagues, the questions on 
the feasibility of screening programs remain unresolved, in particular because of the large 
proportion of false positive CT scans, uncertainties about the target populations and the 
still unknown cost effectiveness of the implementation of screening programs. Notwith-
standing the lack of randomizing screening studies in Switzerland, we feel that it is in 
the interest of the people at risk that they get access to quality-controlled CT screen-
ing at dedicated locations employing multidisciplinary teams, which include specialized 
thoracic surgeons. 
The advances in radio-therapeutic techniques are manifold, and include the optimization 
of radiotherapy planning by FDG-PET as outlined in the article by Schmuecking and 
his team. These results also relate to the delivery of curative-intent radiotherapy, which 
today is restricted to patients not amenable to surgery: ongoing Phase III trials are, how-
ever, evaluating this modality also in patients with operable stage-I cancer. While these 
advances have been based on improvements in technology, the clinical studies have been 
driven by dedicated radio-oncologists focusing on the treatment of lung-cancer patients. 
The challenge will be to introduce these results into the community, as this will require 
a certain specialization also within radio-oncologists.
The composition of the multidisciplinary lung-tumor board has changed. With the ad-
vent of molecular targeted therapy, the pathologist has not only become a key person in 
helping to elaborate lung cancer diagnosis and staging, but also in providing informa-
tion about biomarker testing, in particular for patients beyond the early stages of the 
disease. EGFR-mutation testing has become an integral part of the work-up for the 
determination of rst-line therapy for patients with advanced non-squamous cell lung 
cancer. With the Swissmedic registration of crizotinib the determination of the ALK 
status for decision making in second or further line of therapies is becoming routine. It 
is very likely that additional treatment options will soon become routinely available for 
a small subset of patients with molecularly dened non-small cell lung cancer. The chal-
lenge then will be to provide a maximum of information on a limited amount of tumor 
tissue in a timely fashion and at reasonable costs.
Chemotherapy has improved the outcome of patients with non-small cell lung cancer, as 
we can be observed in the prolonged survival rates in advanced disease and higher cure 
rates for combinations with surgery or radiotherapy for earlier stages of disease. With 
the exception of maintenance therapy, the most recent advances have been achieved in 
selected, molecularly dened subgroups of patients. While the proportion of patients 
with adenocarcinoma and activating EGFR mutations in our environment is about 12%, 
the proportion of patients with the more recently identied oncogenic driver mutations 
is even smaller (1-5%). The rarity of these subsets of the disease is prompting a change 
in the way clinical trials are conceived, as larger-scale molecular testing needs to be per-
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formed to identify patients amenable to molecularly driven treatments. This is a challenge, in 
particular in a small country with a fragmented health system. One approach taken to solve 
the problem was the creation of the European Thoracic Oncology Platform which, supported 
by investigators from Switzerland, provides a network for collaborative translational and 
clinical studies between study groups and dedicated centers within Europe.
Available information suggests that for patients affected by a tumor with activating EGFR 
mutation the integration of getinib or erlotinib in a treatment of advanced disease is associ-
ated with a doubling of survival as compared to a treatment with chemotherapy alone – no 
doubt a clinically signicant improvement. Still, the fact remains, that tumors eventually 
become resistant also to targeted therapies. Thus notwithstanding all advances, patients will 
continue to need support beyond antitumor treatment, including psychological support as 
outlined by Ackeret, as well as supportive care as outlined by Serena. Indirectly, the second 
article also provides some stimulus to remember the fact that nursing is an integral part of 
the multidisciplinary approach and to appreciate the challenges the nursing profession is fac-
ing regarding specialization. 
Individualized care for patients with lung cancer within an integrated system of care provid-
ers has become a reality within a few years and offers patients today a chance for a better out-
come. We will continue to face challenges, including the adoption of internationally accepted 
regulatory decisions, which are better adapted to the new reality of cancer therapy. Notably, 
in the palliative setting, patients’ access to efcient targeted agents must be ensured. For 
example, impressive response rates to a specic agent in the context of limited alternative 
options should be considered a sufcient argument for a provisional approval pending further 
and more denitive outcome data. How to deal with new the opportunities and how to move 
from standardized medicine to personalized medicine must become political priorities. And, 
last but not least, we must consider the question of whether and how society can deal with 
the related costs. This topic has been extensively dealt with in the last issue of this journal.
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